Mesoridazine

Mesoridazine (Serentil) is a piperidine neuroleptic drug belonging to the class of drugs called phenothiazines, used in the treatment of schizophrenia. It is a metabolite of thioridazine. The drug's name is derived from the methylsulfoxy and piperidine functional groups in its chemical structure.

Mesoridazine
Clinical data
Trade namesSerentil
AHFS/Drugs.comMicromedex Detailed Consumer Information
MedlinePlusa682306
Pregnancy
category
  • US: C (Risk not ruled out)
    Routes of
    administration    		Oral, intravenous
    ATC code
    Legal status
    Legal status
    • In general: ℞ (Prescription only)
    Pharmacokinetic data
    Protein binding4%
    MetabolismHepatic/renal
    Elimination half-life24 to 48 hours
    ExcretionBiliary and renal
    Identifiers
    CAS Number
    PubChem CID
    IUPHAR/BPS
    DrugBank
    ChemSpider
    UNII
    KEGG
    ChEBI
    ChEMBL
    CompTox Dashboard (EPA)
    Chemical and physical data
    FormulaC21H26N2OS2
    Molar mass386.576 g/mol g·mol−1
    3D model (JSmol)
    Melting point130 °C (266 °F)
    Solubility in waterinsoluble mg/mL (20 °C)
      (verify)

    It has central antiadrenergic, antidopaminergic, antiserotonergic and weak muscarinic anticholinergic effects.

    Serious side effects include akathisia, tardive dyskinesia and the potentially fatal neuroleptic malignant syndrome.

    Mesoridazine was withdrawn from the United States market in 2004 due to dangerous side effects, namely irregular heart beat and QT-prolongation of the electrocardiogram.[1]

    It currently appears to be unavailable worldwide.

    References
    This article is issued from Wikipedia. The text is licensed under Creative Commons - Attribution - Sharealike. Additional terms may apply for the media files.